Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes

Authors: Fava, D.; Cassone-Faldetta, M.; Laurenti, O.; De Luca, O.; Ghiselli, A.; De Mattia, G.

Source: Diabetic Medicine, Volume 19, Number 9, September 2002 , pp. 752-757(6)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Aims

To evaluate the effects of gliclazide on oxidative status and vascular response to systemic administration of L-arginine, the natural precursor of nitric oxide (NO), in Type 2 diabetic patients. Methods

Thirty Type 2 diabetic patients received glibenclamide (n = 15) or gliclazide (n = 15) in a 12-week, randomized, observer-blinded, parallel study. Plasma lipid peroxides, total radical-trapping anti-oxidant parameter (TRAP), and blood pressure responses to an intravenous bolus of L-arginine were measured pre- and post-treatment. Results

At 12 weeks, gliclazide patients had lower plasma lipid peroxides (13.3 ± 3.8 µmol/l vs. 19.2 ± 4.3 µmol/l; P = 0.0001) and higher plasma TRAP (1155.6 ± 143.0 µmol/l vs. 957.7 ± 104.3 µmol/l; P = 0.0001) than the glibenclamide patients. Gliclazide but not glibenclamide significantly reduced systolic and diastolic blood pressure (P = 0.0199 and P = 0.00199, respectively, two-way repeated measures analysis of variance) in response to intravenous L-arginine. Conclusions

Gliclazide reduces oxidative stress in Type 2 diabetic patients by improving plasma anti-oxidant status. This effect is associated with enhanced NO-mediated vasodilation.

Keywords: gliclazide; vascular function; anti-oxidant status; Type 2 diabetes mellitus

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1464-5491.2002.00762.x

Affiliations: 1: Department of Internal Medicine, University of Rome `La Sapienza', and

Publication date: 2002-09-01